A1. Idilman R, Dökmeci A, Beyler AR, Baştemir M, Örmeci N, Aras N, Ekinci C, Uzunalimoğlu Ö, De Maria N, Van Thiel DH. “Successful medical treatment of an epitheloid hemangoiendothelioma of liver.” Oncology, 54, 171-175 (1997).

A2. Idilman R, De Maria N, Colantoni A, Dökmeci A, Van Thiel DH. “Interferon treatment of cirrhotic patients with chronic hepatitis C.” J Viral Hepat, 4, 81-91 (1997).

A3. Idilman R, De Maria N, Uzunalimoğlu Ö, Van Thiel DH. “Hepatic osteodystrophy.” Hepato-Gastroenterology, 44, 574-581 (1997).

A4. Colantoni A, De Maria N, Idilman R, Van Thiel DH. “Polymerase chain reaction for the detection of HCV-RNA: Cryoglobulinemia as a cause for false negative results.” Ital J Gastroenterol Hepatol, 29, 273-274, (1997).

A5. Akan H, Konuk N, Fenkçi S, Dilek İ, Idilman R, Tuncer S. “Fulminant hepatitis in aplastic anemia: Hepatitis G or ALG?” Bone Marrow Transplant, 21, 533-535 (1998).

A6. Idilman R, De Maria N, Kugelmas M, Colantoni A, Uzunalimoğlu Ö, Van Thiel DH. “Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant.” European J Gastroenterol-Hepatol, 10, 433-436, (1998).

A7. Van Thiel DH, De Maria N, Colantoni A, Idilman R. “Current and future therapies for HCV infection: What should the end point for treatment be?” Hepato-Gastroenterology, 45, 308-320 (1998).

A8. Idilman R, Colantoni A, De Maria N, Van Thiel DH. “Interferon treatment of HCV positive cirrhotic patients.” Hepato-Gastroenterology, 45, 340-344, (1998).

A9. Idilman R, De Maria N, Colantoni A, Dökmeci A, Van Thiel DH. “Pathogenesis of hepatitis B and C induced hepatocellular carcinoma.” J Viral Hepat, 5, 285-289, (1998).

A10. Colantoni A, Hassanein T, Idilman R, Van Thiel DH. “Liver transplantation for chronic viral liver disease.” Hepato-Gastroenterology, 45, 1357-1363 (1998).

A11. Beksaç M, Arat M, Idilman R. “Long-term follow-up and late complications of 2-Chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin’s lymphoma.” Cancer, 85, 242-243, (1999).

A12. Üstün C, Idilman R, Gürman G, Özcan M, Akyol G, Akan H, İlhan O, Beksaç M, Uysal A, Konuk N, Karayalçın S, Poyraz A, Van Thiel DH, Koç H. “Hematopoietic stem cell transplantation in patients with non-replicative hepatitis B virus carriers is safe.” J Hepatol, 31, 202-210, (1999).

A13. Idilman R, Kugelmas M, De Maria N, Van Thiel DH. “Cirrhosis in Turner Syndrome.” European J Gastroenterol-Hepatol, 12, 707-709, (2000).

A14. De Maria N, Idilman R, Colantoni A, Harig J, Van Thiel DH. “Antibody response to HBV vaccination in individuals with HCV infection.” Hepatology, 32, 444, (2000).

A15. Colantoni A, La Paglia N, De Maria N, Emanuele MA, Emanuele NV, Idilman R, Harig J, Van Thiel DH. “Influence of sex hormonal status on alcohol-induced oxidative injury in male and female rat liver.” Alcohol: Clin Exp Res, 24, 1467-1473, (2000).

A16. De Maria N, Colantoni A, Idilman R, Harig J, Van Thiel DH. “The response to interferon+ribavirin retreatment for chronic hepatitis C in interferon non-responders is not influenced by race.” J Hepatol, 33, 1028-1029, (2000).

A17. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. “The impact of previous HBV infection on the course of chronic hepatitis C.” Am J Gastroenterol, 95, 3529-3536, (2000).

A18. Dilek İ, Idilman R, Fenkçi S, Üstün C, Koç H, İlahn O, Akan H. “Immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia.” Turk J Haematol, 17,111-117, (2000).

A19. Idilman R, Üstün C, Aslan Ö, Özcan M, Arat M, Bozkaya H, Bozdayı M, Şengezer T, Uzunalimoğlu Ö, Dökmeci A, İlhan O, Koç H, Akan H. “The incidence of hepatitis G virus in pateints with hematological malignacies: The relationship to the number of blood and blood products transfusions.” Turk J Haematol 16,71-71, (2000).

A20. Van Thiel DH, Brems J, Nadir A, Idilman R, Colantoni A, Holt D, Edelstein S. “Liver Transplantation for fulminant hepatic failure.” J Gastroenterol 36, 1-4, (2001).

A21. Idilman R, Colantoni A, De Maria N, Harig J, Van Thiel DH. “Effect of human immunodeficiency virus on the outcome of hepatitis C virus infection.” Scand J Gastroenterol, 36, 225-234, (2001).

A22. De Maria N, Idilman R, Colantoni A, Van Thiel DH. “Increased effective immunogenicity to high dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis.” J Viral Hepat, 8, 372-376, (2001).

A23. Idilman R, Çetinkaya H, Savaş İ, Aslan N, Sak SD, Baştemir M, Sarıoğlu M, Soykan İ, Bozdayı M, Colantoni A, Aydıntuğ O, Bahar K, Uzunalimoğlu Ö, Van Thiel DH, Numanoğlu N, Dökmeci A. “Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C.” J Med Virol, 66, 34-39, (2002).

A24. Idilman R, De Maria N, Colantoni A, Nadir A, Van Thiel DH. “The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C.” Am J Gastroenterol, 97, 435-439, (2002).

A25. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. “Impaired response to high dose interferon treatment in African-American with chronic hepatitis C.” Hepato-Gastroenterology, 49, 788-792, (2002).

A26. Soykan İ, Törüner M, Sarıoğlu M, Idilman R. “Is pain experienced during liver biopsy an important factor.” Clin Gastroenterol, 35, 202-203, (2002).

A27. Örmeci N, Soykan İ, Palabıyıkoğlu M, Idilman R, Erdem H, Bektaş A, Sarıoğlu M. “A new therapeutic approach for the treatment of hydatid cysts of the spleen.” Dig Dis Sci, 47, 2037-2044, (2002).

A28. Soykan İ, Törüner M, Idilman R, Özden A. “Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyprohepatadine.” J Clin Gastroenterol, 36, 183-184, (2003).

A29. Idilman R, Colantoni A, De Maria N, Üstün C, Sam R, Ing TS, Akan H, Koç H, Van Thiel DH. “Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals.” Hepato-Gastroenterology, 50, 217-221, (2003).

A30. Colantoni A, Idilman R, De Maria N, La Paglia N, Belmonte J, Wezeman F, Emanuele N, Van Thiel DH, Kovacs EJ, Emanuele MA. “Hepatic apoptosis and proliferation in male and female rats fed alcohol: Role of cytokines.” Alcohol Clin Exp Res, 27, 1184-1189, (2003).

A31. Idilman R, Üstün C, Karayalçın S, Aktemel A, Türkyılmaz A, Özcan M, Arslan Ö, Bozdayı AM, Van Thiel DH, Akan H. “Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.” Clin Transplant, 17, 438-443, (2003).

A32. Idilman R, Arat M, Soydan E, Törüner M, Soykan İ, Akbulut H, Arslan Ö, Özcan M, Türkyılmaz AR, Bozdayı M, Karayalçın S, Van Thiel DH., Beksaç M, Akan H. “Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.” J Viral Hepatitis, 11, 141-147, (2004).

A33. Idilman R, Colantoni A, De Maria N, Alkan S, Nand S, Van Thiel DH. “Lymphoproliferative disorders in chronic hepatitis C.” J Viral Hepatitis, 11, 302-309, (2004).

A34. Soykan A, Boztas H, Idilman R, Ozel ET, Tuzun AE, Ozden A, Ozden A, Kumbasar H. “Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables.” Int J Impot Res, 17,175-179, (2005).

A35. Idilman R, Erden E, Kuzu I, Ersoz S, Karasu Z, Karayalcin K, Yuce G, Tokat Y, Sahin Y, Tukun A, Akarca US, Karayalcin S. “Recipient-derived hepatocytes in sex-mismatched liver allografts after liver transplantation: early versus late transplant biopsies.” Transplantation, 78, 1647-1652, (2004).

A36. Ensari A, Savas B, Okcu Heper A, Kuzu I, Idilman R. “An unusual presentation of Helicobacter pylori infection: so-called "Russell body gastritis". Virchows Arch, 446, 463-466, (2005).

A37. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother, 55, 828-831, (2005).

A38. Bozkaya H, Yurdaydin C, Idilman R, Tuzun A, Cinar K, Erkan O, Bozdayi AM, Erden E, Uzun Y, Cetinkaya H, Uzunalimoglu O. “Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.” Antivir Ther, 10, 319-325, (2005).

A39. Bozdayi G, Turkyilmaz AR, Idilman R, Karatayli E, Rota S, Yurdaydin C, Bozdayi AM. “Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from turkish patients with chronic HBV infection.” J Med Virol, 76, 476-481, (2005).

A40. Idilman R, Erden E, Arat M, Soydan E, Erkan O, Kuzu I, Sahin Y, Coban S, Bozdayi M, Giraud A, Akan H, Karayalcin S, Ozden A. “Trefoil factor expression in biliary epithelium of graft-versus-host disease of the liver after allogeneic hematopoietic cell transplantation.” Transplantation, 80,1099-1104, (2005).

A41. Verdi H, Koytak ES, Onder O, Ergul AA, Cinar K, Idilman R, Erden E, Bozdayi AM, Yurdaydin C, Uzunalimoglu O, Bozkaya H. “Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis.” J Investig Med, 53, 353-359, (2005).

A42. Idilman R, Kuzu I, Erden E, Arat M, Soydan E, Soykan I, Akyol G, Karayalcin S, Akan H, Beksac M. “Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation.” Bone Marrow Transplant, 37, 199-206 (2006).

A43. Ormeci N, Idilman R, Tuzun A, Erdem H, Palabiyikoglu M. “A new percutaneous approach for the treatment of hydatid cyst of the kidney: long-term follow-up.” Int Urol Nephrol 37, 461-464, (2005).

A44. Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalcin S, Akan H. “Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.” Clin Transplant, 19, 798-803, (2005).

A45. Coban S, Palabiyikoglu M, Ensari A, Idilman R, Koklu S, Yolcu OF, Ormeci N. “Intestinal B cell lymphoma associated with chronic hepatitis C and celiac disease.” Dig Dis Sci, 50, 2359-2361, (2005).

A46. Idilman R. “Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy” Minerva Gastroenterol Dietol, 52, 39-45 (2006).

A47. Cinar K, Coban S, Idilman R, Tuzun A, Sarioglu M, Bektas M, Erden E, Bozkaya H, Ozden A. “Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?” J Gastroenterol Hepatol, 21, 169-173 (2006).

A48. Uzun Y, Bozkaya H, Erden E, Cinar K, Idilman R, Yurdaydin C, Uzunalimoglu O. “Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment.” J Gastroenterol Hepatol, 21, 977-981, (2006).

A49. Turkcapar N, Ozyuncu N, Idilman R, Ensari A, Soylu K, Ozden A. “Macro-amylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies.” Turk J Gastroenterol, 17, 140-143 (2006).

A50. Idilman R. “Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.” Gut, 55, 1208-109, (2006).

A51. Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. “Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy.” Liver Transpl, 12, 1427-1430, (2006).

A52. Turkcapar N, Ozyuncu N, Cinar K, Ensari A, Kucuk O, Idilman R, Duman N, Ozden A. “A case of systemic lupus erythematosus presenting with protein losing enteropathy.” Turk J Gastroenterol, 17, 226-230 (2006).

A53. Ormeci N, Idilman R, Akyar S, Palabiyikoglu M, Coban S, Erdem H, Ekiz F. “Hydatid cysts in muscle: a modified percutaneous treatment approach.” Int J Infect Dis, 11, 204-208 (2007).

A54. Idilman R, Erden E, Kuzu I, Ersoz S, Karayalcin S. “The fate of recipient-derived hepatocytes in sex-mismatched liver allograft following liver transplantation.” Clin Transpl, 21, 202-206, (2007).

A55. Arat N, Kacar S, Golbasi Z, Akdogan M, Somken Y, Kuran S, Idilman R. “P wave dispersion is prolonged in patients with Wilson’s disease.” Worl J Gastroenterol, 28, 1252-1256 (2008).

A56. Bektas M, Idilman R, Soykan I, Soydan E, Arat M, Cinar K, Coban S, Tuzun A, Bozkaya H, Ormeci N, Ozden A. “Adjuvant therapeutic plasma Exchange in liver failure: assessments of clinical and labratory parameters. J Clin Gastroenterol, 42, 517-521 (2008).

A57. Idilman R, Dilsa M, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A. “Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resitance in individuals with non-alcoholic steatohepatitis.” Aliment Pharmacol Ther 28, 200-208 (2008).

A58. Koytak ES, Mizrak, Bektas M, Verdi H, Arslan A, Idilman R, Cinar K, Yurdaydin C, Ersoz S, Karayacin K, uzunalimoglu O, Bozkaya H. “PPAR-alpha L162V polymorphism in human hepatocellular carsinoma. Turk J Gastroenterol, 19, 245-249 (2008).

A59. Arat M, Idilman R. “Hepatic complications of allogeneic hematopoietic cell transplantation.” Turk J Hematolol 25,111-123, (2008).

A60. Erden A, Idilman R, Erden I, Ozden A. “Veins around the esophagus and the stomach: do their calibrations provide a diagnostic clue for portal hypertensive gastropathy.” Clin Imaging, 33, 22-24 (2009).

A61. Idilman R, Kaymakoglu S, Onder O, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Bozdayi AM, Bozkaya H, Otken A, Yurdaydin C. “A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.” J Viral Hepat, 16, 279-285 (2009).

A62. Korkut E, Bektas M, Savas B, Memmedzade F, Oztas E, Ustün Y, Idilman R, Ozden A. “Awareness of the endoscopist affects detection rate of heterotopic gastric mucosa in esophagus.” Ind J Gastroenterol 28, 75-76 (2009).

A63. Mizrak D, Engin B, Onder FO, Yener B, Bektaş M, Biyikli Z, Idilman R, Cinar K, Karayalçin K, Ersöz S, Karayalçin S, Ozden A, Yurdaydin C, Yazihan N, Ataoğlu H, Bozkaya H, Uzunalimoğlu O. “Aflatoxin exposure in viral hepatitis patients in Turkey.” Turkish J Gastroenterol 20, 192-197, (2009).

A64. Bektas M, Dokmeci A, Cinar K, Halici I, Oztas E, Karayalcin S, Idilman R, Sarioglu M, Ustun Y, Nazlıgul Y, Ormeci N, Ozkan H, Bozkaya H, Yurdaydin C. “Endoscopic mamangement of biliary parasitic diseases.” Dig Dis Sci 55, 1472-1478, (2010).

A65. Mızrak D, Bektaş M, Kaygusuz G, Cinar K, Idilman R, Ozden A. “Gastric aberrant pancreas.” Turkish J Gastroenterol 21, 68-69, (2010).

A66. Idilman R, Bektaş M, Cinar K, Toruner M, Cerit ET, Doğanay B, Erden E, Bozkaya H, Bahar K, Karayalcin S, Soykan I, Palabiyikoglu M, Cetinkaya H, Yurdaydin C, Dokmeci A, Ozden A. “The characteristics and clinical outcome of drug-induced liver injury: a single-center experience.” J Clin Gastroenterol, 44, 128-132, (2010).

A67. Erden A, Idilman R, Erden I, Bektaş M, Ozden A. “MR angiography of esophageal mural veins in protal hypertension: a correlation with endoscopic grades of esophageal varices.” Turkish J Gastroenterol 21, 275-79, (2010).

A68. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi M. “Natural history and treatment of chronic delta hepatitis.” J Viral Hepat, 17, 249-56, (2010).

A69. Idilman R, Bozkus Y, Seval G, Mizrak D, Cinar K, Ustun Y, Bektas M, Arat M, Akbulut H, Doganay B, Ozden A. “Lymphoproliferative disorders in individuals with chronic hepatitis B and C in the Turkish population.” J Med Virol 83, 974-980, (2011).

A70. Idilman R, Arat M. “Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.” Expert rev Anti Infect Ther 9, 641-652, (2011).

A71. Coban S, Idilman R, Erden E, Tuzun A. “Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.” Hepatogastroenterology 58, 1301-1306, (2011).

A72. Celik I, Karatayli E, Cevik E, Kabakci SG, Karatayli SC, Dinc B, Cinar K, Yalcin K, Idilman R, Yurdaydin C, Bozdayi AM. “Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients.” Arch Virol 156, 2215-2220, (2011).

A73. Seven G, Cinar K, Yakut M, Idilman R, Ozden A. “Assesment of helicobacter pylori eradication rate of triple combination therapy containing levofloxacin.” Turk J Gastroenterol 22,582-586, (2011).

A74. Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Guven K, Idilman R, Yurdaydin C, Bozdayi AM. “Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.” J Clin Virol 53, 130-134, (2012).

A75. Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. “Hepatitis B surface antigen seroconversion is associated wit favourable long-term clinical outcomes during lamivudine treatment in HBeAg negative chronic hepatitis B patients.” J Viral Hepat 19, 220-226, (2012).

A76. Bozdayi AM, Karatayli SC, Alagöz SG, Mizrak D, Sayki M, Ozkan M, Savaş B, Erden E, Cinar K, Idilman R, Yurdaydin C. “Potential biomarkers in assessing liver fibrosis using SELDI-TOF MS.” Turk J Gastroenterol 23, 46-53, (2012).

A77. Kabaçam G, Onder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, Savas B, Idilman R, Bozdayi AM, Yurdaydin C. “Entecavir treatment of chronic hepatitis d.” Clin Infcet Dis 55, 645-650, (2012).

A78. Heidrich B, C Serrano B, Idilman R, Kabaçam G, Bremer B, Raupach R, Onder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. “HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome.” Liver Int 32, 1415-1425, (2012).

A79. Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. “The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.” Eur J Health Econ 13, 663-676, (2012).

A80. Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi AM, Yurdaydin C. “Clonal analysis of the quasispecies of antiviral resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.” Antivir Ther (2012).

A81. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M, Fitch WL, Peltz G. “Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction.” J Pharmacol Exp Ther 344, 388-396, (2013).

A82. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, Celik A, Bahar K, Karcaaltincaba M. “Hepatic steatosis: quatification by proton density fat fraction with MR imaging versus liver biopsy.” Radiology 267, 767-775, (2013).

A83. Celebi ZK, Sengul S, Soypacaci Z, Yayar O, Idilman R, Tuzuner A, Keven K. “Kidney transplantation from hepatitis B (HB)-positive donors to HB negative recipients: anti-HB Core immunoglobulin G became positive in all recipients after the transplantation.” Transpl Proc 45,923-925, (2013).

A84. Bakanay ŞM, Bilgin AU, Bektaş M, Idilman R, Erden E, Arat M, Arslan Ö. “Vanishing bile duct syndrome after allogeneic bone marrow transplantation: is it the end of the road?” Turk J Gastronetrol 24,359-362, (2013).

A85. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; the HIDIT-1 Study Group. “Role of immunhistochemistry for hepatitis D and hepatitis B virus in hepatitis delta.” Liver Int 34,1207-15, (2014).

A86. Keskin O, Ormeci AC, Baran B, Kabaçam G, Tuzun A, Karatayli E, Akyüz F, Karatayli S, Bozdayi AM, Onel D, Badur S, Idilman R, Kaymakoglu S, Yurdaydin C. “Efficacy of tenofovir in adefovir experienced patients compared to treatment-naïve patients with chronic hepatitis B.” Antiviral Ther 19,543-50, (2014).

A87. Bektas M, Seven G, Idilman R, Yakut M, Doğanay B, Kabacam G, Ustun Y, Korkut E, Kalkan C, Sahin G, Cetinkaya H, Bozkaya H, Yurdaydin C, Bahar K, Cinar K, Soykan I. “Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis.” Eur J Intern Med 25,230-234, (2014).

A88. Karataylı E, Altunoğlu YC, Karataylı SC, Alagöz SG, Cınar K, Yalçın K, Idilman R, Yurdaydın C, Bozdayı AM. “A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control.” J Clin Virol 60,11-15, (2014).

A89. Karatayli SC, Ulger ZE, Ergul AA, Keskin O, Karatayli E, Albayrak R, Ozkan M, Idilman R, Yalcin K, Bozkaya H, Uzunalimoğlu O, Yurdaydin C, Bozdayi AM. “Tumor necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gen polymorphisms in patients with chronic hepatitis delta.” J Viral Hepat 21,297-304, (2014).

A90. Idilman IS, Keskin O, Elhan AH, Idilman R, Karcaaltincaba M. ''Impact of sequential proton density fat fraction for quantification of hepatitc steatosis in nonalcoholic fatty liver disease. " Scand J Gastroenterol 49,617-624, (2014).

A91. Sayki Aslan M, Turhan S, Dincer I, Mizrak D, Corapcioğlu D, Idilman R. "A potential link between endothelial function,cardiovascular risk, and metabolic syndrome in patients with non-alcoholic fatty liver disease." Diabetol Metab Sybdr 14,106, (2014).

A92. Kabakçı Alagöz G, Karataylı SC, Karataylı E, Celik E, Dinç O, Dinç B, Cınar K, Idilman R, Yurdaydın C, Bozdayı AM. "Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade:performance of pyhlogenetic analysis of the NS5B,E1 and 5'UTR regions in genotyping efficiency." Turk J Gastroenterol 25,405-410, (2014).

A93. Gürakar M, Malik M, Keskin O, Idilman R. "Public awareness of hepatitis B infection in Turkey as amodel of universal effectiveness in health care policy." Turk J Gastroenterol 25,304-308, (2014).

A94. Seven G, Çınar K, Idilman R, Tüzüner A, Hazinedaroğlu S, Karayalçın S, Bahar K. "Endoscopic treatment of biliary complications following liver transplantation." Turk J Gastroenterol 25,156-161, (2014).

A95. Wedemeyer H, Duberg AS, Buti M, Rosenbverg WM, Idilman R, et al. "Strategies to manage hepatitis C virus (HCV) disease burden." J Viral Hepat 21,60-89, (2014).

A96. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, et al."The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm."J Viral Hepat 21,34-59, (2014).

A97. Bruggmann P, Berg T, Qvrehus AL, Moreno C, Idilman R, et al. "Historical epidemiology of hepatits C virus (HCV) in selected countries." J Viral Hepat 21,5-33, (2014).

A98. Keskin O, Idilman R. "Sequential development of acute autoimmune hepatitis may lead to aserious clinical picture in primary biliary cirrhosis." Eur J Gastroenterol Hepatol 27,1228-1229, (2015).

A99. Yurdaydin C, Idilman R."Therapy of Delta Hepatitis." Cold Spring Harb Perspect Med 7, (2015).

A100. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V,Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. "Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial." Lancet Infect Dis 15,1167-1174, (2015).

A101. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. "Seroprevalence of hepatittis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study." Clin Microbiol Infect 21,1020-1026, (2015).

A102. Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. "Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome." Clin Gastroenterol Hepatol 13,2342-2349, (2015).

A103. Soydal C, Keskin O, Kucuk ON, Ozkan E, Bilgic S, Idilman R, Kir MK. "Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy." Ann Nucl Med 29,426-430, (2015).

A104. Idilman IS, Tuzun A, Savas B, Elhan AH, Celik A, Idilman R, Karcaaltincaba M. "Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. "Abdom Imaging 40,1512-1519, (2015).

A105. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. "Long-term entecavir or tenofovir disoprpxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting." J Viral Hepat 22:504-510, (2015).

A106. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group. "Adding pegylated inferferon to entecavir for hepatitis B antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study)" Hepatology 61:1512-1522, (2015).

A107. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J,Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. "Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir." J Hepatol 62, 363-370, (2015).

A108. Karataylı SC, Bozdayı M, Karataylı E, Oztürk T, Husseini AA, Albayrak R, Ozkan M, Kalaylıoğlu Z, Yalçın K, Cınar K, Idilman R, Yurdaydın C. “Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B.” Liver Int 35, 846-853, (2015).

A109. Soydal C, Aslan MF, Kucuk ON, Idilman R, Bilgic S. "Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C heatocellular cancer patients" Nuci Med Commun, 37, 646-649, (2016).

A110. Idilman IS, Keskin O, Celik A, Savas B, Halil Elhan A, Idilman R, Karcaaltincaba M. "A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non alcoholic fatty liver disease." Acta Radiol 57, 271-278, (2016).

A111. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Gouslis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy." J Hepatol, 64, 800-806, (2016).

A112. Idilman R, Erden A, Karakaya F. “Stone-containing cytic mass at the portal hilus of the liver in an asymptomatic young female patient.” Gastroenterology, 151, 9-10, (2016).

A113. Idilman R, Akyildiz M, Keskin O, Gungor G, Yilmaz TU, Kalkan C, Dayangac M, Cinar K, Balci D, Hazinedaroglu S, Tokat Y. “The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-trasplant hepatitis B virus recurrence.” Clin Transplant, 30, 1216-1221 (2016).

A114. Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. “Non-invasive fibrosis score for hepatitis delta.” Liver Int, 37, 196-204 (2017).

A115. Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. ''Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.'' Hepatol Commun, 19, 288-292 (2017).

A116. Kaymakoğlu S, Köksal İ, Tabak F, Akarca US, Akbulut A, Akyüz F, Bodur H, Çağatay A, Dinçer D, Esen Ş, Güner R, Gürel S, Köse Ş, Şentürk Ö, Şimşek H, Yamazhan T, Yılmaz Y, Idilman R, Guidelines Study Group VH. ''Recommendation for treatment of hepatitis C virus infection.'' Turk J Gastroenterol (2017)

A117. Idilman R, Baykam N, Kaymakoğlu S, Tabak F, Bahçecioğlu HI, Bektaş A, Bulut C, Günşar F, İnan D , Karaosmanoğlu HK, Karasu Z, Kuşçu F, Mete B, Özbakır Ö, Özdoğan OC, Parlak M, Sırmatel F, Topalak Ö, Ünsal B, Guidelines Study Group VH. ''Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus.'' Turk J Gastroenterol, 28, 90-93 (2017).

A118. Yurdaydın C, Tabak F, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ, Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, Guidelines Study Group VH. ''Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines.'' Turk J Gastroenterol, 28, 84-89 (2017).

A119.Tabak F, Yurdaydın C, Kaymakoğlu S, Akarsu M, Akıncı EG, Akkız H, Alkım C, Çekin AH, Çuvalcı NÖ, Demir K, Değertekin B, Dökmetaş İ, Ersöz G, Hizel K, Kandemir FÖ, Önlen Y, Sonsuz A, Şenateş E, Tosun S, Tözün N, Idilman R, Guidelines Study Group VH. ''Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines'' Turk J Gastroenterol, 28, 73-83, Dec (2017).

A120. Idilman R. ''Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines. '' Turk J Gastroenterol, 28, 518-521 (2017).

A121. Idilman R.''The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection'' Turk J Gastroenterol, 28, 412-416 (2017).

A122. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. ''The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B'' Hepatology, 66, 1444-1453 (2017).

A123. Polaris Observatory HCV Collaborators. '' Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. '' Lancet Gastroenterol Hepatol, 2, 161-176 (2017).

A124 Karakaya F, Özer S, Kalkan Ç, Tüzün EA, Çalışkan A, Keskin O, Kabaçam G, Karatayli S, Karatayli E, Bozdayi AM, Idilman R, Yurdaydin C.'' Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up.'' Antivir Ther, 22, 559-570 (2017).

A125. Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS. ''Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.'' Hepatology 1224-1236 (2018).

A126 Hesimov I, Kirimker EO, Duman B, Keskin O, Cetinkaya OA, Hayme S, Ustuner E, Idilman R, Yurdaydin C, Dokmeci A, Kumbasar H, Yilmaz AA, Kologlu MB, Karayalcin K, Balci D.'' Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study.'' Transplant Proc, 50, 3076-3081 (2018).

A127 Zeybel M, İdilman R. ''Serum biomarkers for the evaluation of liver fibrosis: The need for better tests.''Turk J Gastroenterol, 29, 377-378, (2018)

A128. Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Manns MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B. '' Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.'' J Viral Hepat, 25, 1384-1394 (2018).

A129. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. ''Eight-year survival in chronic hepatitis B patients under longterm entecavir or tenofovir therapy is similar to the general population.'' J Hepatol, 68, 1129-1136 (2018).

A130. Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çaliskan A, Kabaçam G, Önder FO, Karatayli S, Karatayli E, Deda X, Bozkaya H, Bozdayi AM, Idilman R. ''Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.'' J Infect Dis, 28, 1184-1192 (2018).

A131. Köklü S, Köksal I, Akarca US, Balkan A, Güner R, Demirezen A, Sahin M, Akhan S, Ozaras R, Idilman R. Daclastasvir plus asunaprevir dual therapy for chronic hepatitis HCV genotype 1 b infection: result of Turkish Early Access Program. Ann Hepatol, 16, 71-76 (2017).

A132. Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D, White MB, Karakaya F, Wang J, Atalay R, Hylemon PB, Gavis EA, Brown R, Thacker LR, Acharya C, Heuman DM, Sikaroodi M, Gillevet PM. '' Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort.'' Hepatology, 68, 234-247 (2018).

A133. Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. '' Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.'' Lancet Infect Dis 19, 275-286 (2019).

A134. Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S, Akarca US; Early Access Program (EAP) Study Group. ''Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.'' J Viral Hepat, 26, 666-674 (2019).

A135. van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. ''Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up.'' J Viral Hepat, 26, 109-117 (2019).

A136. Ataca Atilla P , Yalçıner M , Atilla E , Idilman R , Beksaç M. ''Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib.'' Turk J Haematol, 36, 266-273 (2019)

A137.Cox IJ, Idilman R, Fagan A, Turan D, Ajayi L, Le Guennec AD , Taylor-Robinson SD, Karakaya F, Gavis E, Andrew Atkinson R, Williams R, Sikaroodi M, Nizan S, Gillevet PM, Bajaj JS. ''Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis.'' Liver Int, 40, 416-417(2020)

A138.Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H , Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Estebean R, Janssen H, Berg T , Lampertico P. '' J Hepatol, 22 (2020)